前苏联专利SU1498383A3 Method of producing derivatives of aminoguanidine or their acid-additive salts

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
The invention relates to new aminoguanidine derivatives of the general formula (I), <IMAGE> I wherein R1, R2 and R3 each represent hydrogen or halogen atom, C1-4 alkyl, nitro, trifluoromethyl or C1-4 alkoxy group, R4 and R5 represent a C1-4 alkyl group, furthermore NR4R5 may form a 5 to 7 membered saturated heterocyclic group containing either one or two nitrogen atoms or a nitrogen and an oxygen atom and being optionally substituted by one or two methyl, hydroxymethyl or hydroxyethyl groups, R6 and R7 each represent a hydrogen atom, normal or branched C1-4 alkyl or C2-4 alkenyl group, and to their pharmaceutically acceptable acid addition salts as well as to a process for the preparation thereof. The new compounds of the invention possess valuable antiarrhythmic activity and are devoid of the undesired circulatory side effects of the known antiarrhythmic compounds.
公开号:SU1498383A3
申请号:SU853969348
申请日:1985-10-28
公开日:1989-07-30
发明作者:Эрци Иштван；Марошфалфи Иене；Раблоцки Дьердь；Варро Андраш；Кухар Мариа；Элекеш Иштван；Сатмари Ласло；Яслитш Ласло
申请人:Биогал Дьедьсердьяр (Инопредприятие)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of new derivatives of aminsguanidine, of the formula
Nr6
where R and R 2 independently of one another denote hydrogen or chlorine, or C -C-alkyl; Rj is hydrogen;
R and R 5 are e zlkyl or they can form a 5–7-membered saturated heterocyclic group with one nitrogen atom and one oxygen atom.

s / 1
3149
which, if necessary, can be evlocated by one or two methyl groups; R J is hydrogen or C 1-C3 alkyl;
R is hydrogen,
or their acid addition salts exhibiting antiarrhythmic activity.
The aim of the invention is to find new compounds that have increased antiarrhythmic activity in comparison with the known compounds of the same purpose and at the same time have no harmful side effects on the circulation.
Antiarrhythmic effect is tested using the following methods.
Akonitinova arrhythmias in mice. In male mice weighing 20–25 g with continuous infusion of aconitine (0.2 ml / min, concentration 5 mg / kg) cause arrhythmia, a substance being tested
intravenous dosing
(injected into the abdominal cavity) 15 minutes, orally 60 minutes before the start of the infusion. The time of onset of arrhythmia, or delay of onset, is measured and expressed as a percentage compared with 0.9% sodium chloride solution in pretreated control animals.
The results are shown in Tables 1 and 2. 1- (2,6-dimethyl-phenoxy) -2-aminopropane-hydrochloride (mexiletin) and / or quinidine are used as a substance for comparison.
Table 1 presents the study of the antiarrhythmic effect of aconitic arrhythmias on anesthetized mice after intragastric administration of the test compound.
Table 2 shows the study
antiarrhythmic effect in aconitic arrhythmias on anesthetized mice at oral administration
test compound.
Fibrillation threshold measurement in anesthetized cats. At the heart of a cat whose chest cell is opened under the action of chloralose-urethane, anesthesia, a bipolar electrode is sewn, as a result of which, with r the rising current intensity, they are irritated with electrical frequency of 20 Hz,
five
0
five
0
five
0
five
0
,
no fibril qi is established in the heart. This current is regarded as the threshold of fibrillation of the animal, studies are conducted to what extent the known anti-arrhythmic agents or compounds of the invention increase this value in intravenous (i.v.) or intraduodenal (i.d.) administration.
The measured values are summarized in Tables 3 and 4.
In tab. Figure 3 shows the effect of the compounds studied on the threshold of 4 1brillation in anesthetized cats after intravenous administration.
Table 4 shows the effect of the compounds studied on the fibrillation threshold in cats treated with anesthesia after intraduodenal administration.
Electrophysiological measurements on an isolated rabbit heart. Right and left heart valves or a strip of the right ventricle of male and female rabbits weighing 1-2 kg are dissected and placed in a solution with organs that contain a liquid nutrient medium. When using bipolar discharge and irritating platinum electrodes, an electric stimulation threshold is measured conduction of stimulation and with the help of a maximum, maximum drive speed effective refractory period. The results are read from the oscilloscope screen.
The research results are summarized in table 5. The electrophysiological activity of the compounds of the invention is shown by the example of 1- (2-methyl-phenyl) -4,4-dimethyl-aminoguanidine hydrochloride (example 1).
Table 5 shows that time is about. maintain irritation in both the left heart valve and in the right ventricle, depending on the dose, lengthen with the compounds of the invention, which means a decrease in the rate of stimulation. The connection reduces the maximum purity of the drive, which entails a lengthening of the refractory period. The atrial capacity for contraction, although dose dependent, is only slightly reduced by the compound.
Example 1. 1- (2-Methyl-phenyl) -4,4-dimethyl-aminoguanidine, -hydrochloride.
A solution of 3.23 g (0.01 mol) of 1- (2-methyl-phenyl (-3- (3-methyl) -isothioisecarbaeid hydroiodide in 10 ml of ethanol) is mixed with 10 ml of dimethyl amine solution (33% in absolute ethanol) and the solution is stirred at 25 ° C for 72 hours. During the reaction, gaseous methyl mercaptan is liberated. After the complete reaction, the solution is evaporated in a vacuum, the residue is dissolved in 15 ml of water, the solution is cooled to pH adjusted using solid bicarbonate sodium between 8 and 9. The beige precipitated product is filtered on a glass filter and washed with ice water. The filter was dissolved at room temperature in 15 ml of hydrochloric acid, treated with activated carbon and evaporated in vacuo. The dry residue was dissolved in 4 ml of hot ethanol, the opaque solution was filtered, the filtrate was cooled to room temperature and mixed with 16 ml of hexane. The precipitated white crystalline substance is filtered on a glass filter, washed with a mixture of hexane: ethanol 4: 1 and dried. Yield 0.94 g (41%), mp: 2-1-22-22 c.
Example 2. 1- (2,6-Dichlorophenyl) -4, 4-dimethylaminoguanidine.
A solution of 3.78 g (0.01 mol) of 1- (2,6-dichlorophenyl) -3- (S-methyl) isothiose carbazide hydroiodide in 12 ml of ethanol is mixed with 5 ml of a 33% solution of diethylamine in abs.ethanol, solution g rcms 1 is kept for 72 hours. bo tJpeM -. The reaction releases gaseous meelmercaptan. After the reaction is complete, the solution is evaporated in vacuo, the residue is dissolved in 15 ml of water, cooled to and adjusted to pH1 with solid sodium bicarbonate between 8 and 9. The beige precipitated product is filtered on a glass filter and washed ice water. This wet filter mass is dissolved at room temperature in 15 ml of hydrochloric acid, treated with activated carbon and evaporated in vacuo. The dry residue is dissolved in hot (8 ml) ethanol, the solution is cooled to 30-40 ° C and mixed with 32 MP of hexane.
The precipitated white crystalline substance is cooled to O C and
8383

then filtered on a glass filter, washed with a 4: 1 mixture of hexane: ethanol and dried. Yield 1.31 g (m.p .: 255-257 C.
Examples 5-19. The compounds listed in Table 6 are prepared according to examples 1-2.

Example 20. 1- (2-Chlorophenyl) - 4,4 - diethyl-aminoguanidine-hydrochloride.
To a solution of 3.44 g (0.01 mol) of 1- (2-) 5 chlorophenyl) -3- (5-methyl) -isosemicarbazide-hydroiodide in 10 ml of ethanol was added 0.73 g (0.01 mol). ) fresh distilled diethylamine, and the solution is stirred at 40 ° C for 72 hours. During the reaction, vyde20
five
0
five
0
0
five
five
is methyl mercaptan. After completion of the reaction, the solvent is distilled off in vacuum, the residue is dissolved in 10 ml of water, cooled to, the pH value is adjusted to a value of 8-9 with solid sodium bicarbonate, then the separated substance is filtered and washed with water with temperature. The wet wet substance is dissolved at room temperature in 15 ml of n. hydrochloric acid, clarified with activated carbon, then evaporated to dryness in vacuo. The evaporation residue is dissolved in a mixture of 10 ml of acetone and 2 ml of zthanol in the form of heat, then cooled to room temperature, and then 25 ml of ether are added to the mixture. After cooling, the isolated product is filtered, washed with a mixture of ether and acetone in the ratio 3: 1 and dried. The weight of the obtained product is 1.02 g (35%). M.p. 216.5-217 ,.
I
Example 21. 1- (2-Methyl-phenyl) -4,4-diethyl-aminoguanidine hydrochloride.
A solution of 3.23 g (0.01 mol) of 1- (2-methyl-phenyl) -3- (S-methyl) -isothio-semicarbazide hydroiodide in 10 ml of ethanol is mixed with 0.73 g (0.01 mol) freshly distilled diethylamine, the solution was stirred at 40 ° C for 72 hours. Methyl mercaptan gas exuded during the reaction. After the completed reaction, the solution is evaporated in vacuo, the residue is dissolved in 10 ml of water, the solution is cooled to
and adjusting the pH with solid sodium bicarbonate between 8 and 9. The beige precipitated product is filtered on a glass filter and washed with ice water. This wet filter mass is dissolved at room temperature in I3 ml of hydrochloric acid, treated with activated carbon and evaporated in vacuo. The dry residue is dissolved in a hot mixture of 10 MP acetone and 2 ml of ethanol, the opaque solution is filtered, the filtrate is cooled to room temperature and mixed with 25 ml of ether. The beige precipitated crystalline substance is cooled before and then filtered on a glass filter, washed with a mixture of ether and acetone 3: 1 and dried. Yield 0.95 g (37Z), m.p. 174-17b with.
Thus, the compounds of the invention are superior in their effect to the antiarrhythmic agent, 1- (2,6-dimethyl-phenoxy) -2-amino-propane-hydrochloride (mexiletin) and at the same time do not have any typical adverse side effects on the blood circulation ( a decrease in pressure in the pulmonary circulation, an increase in pressure in the pulmonary circulation, bradycardia in animals with an intact chest or in anesthesia, constantly having a cannula) in the dose range of 0.5-4.0 mg / kg. In addition, they do not affect the autonomic nervous system, therefore, the compounds have no activity (/ - or | 3-adrenergic blockers, nor adrenergic neuroblockers or parasympatholytic activity.
The compounds according to the invention also have a significant cardioprotective effect, three times the cardioprotective aktivnosti diethylaminoacet- (2,6-dimethyl) -amylide (lidocaine). For therapeutic purposes, provide a daily dose of 75 mg / / 70 kg body weight.

权利要求:
Claims (1)
[1]
The invention The method for the preparation of aminoguanidine derivatives of general formula I
6 „
and N-NH-C-КС
i 5 7
de R and
“3-5 is independently hydrogen, or chlorine, or C, -C-alkyl; hydrogen;
C, -C5-alkyl or can form a 5-7-membered saturated heterocyclic group with one nitrogen atom or one nitrogen atom and one oxygen atom, which can be substituted with one or two methyl groups if necessary; hydrogen or C-C d-alkyl;
R -, hydrogen,
are their acid addition salts, which is due to the fact that the hydrochloric acid salt of isothiami-arbazide of the general formula II
RI
RS
R NRe
N-nH-i - scHs
R2 7
where R, -Rj, R have specified
meanings
treat with secondary amine of general formula IIIR
WITH
R5
where R5 has the indicated values, in the presence of a solvent, cyclohexanol or aliphatic alcohol at 20-40 ° C, followed by separation of the free base of general formula I from its salt and / or transferring it to another acid addition salt.
,
The compound is toxic at a higher dose.
The compound is toxic at an elevated dose and causes bradycardia.
eleven
1498383
12
1314983831
Table
In the right ventricle
Amendment-By application- +0.2 +3.31 +14.85 +36.75 +52.45 +77.82
Impact time 1 + 11
meniMexile
provisibility
Amendment-By application- About -1.43 +5.42 +20.6 +23.6 +35.8
runner 1 + 6
elek-meksiletriches-ting whom threshold of irritation
Revised by App 0,88 -0,38 -1,82 -10,33 -17,43 -36,8
1-27 Macro
Simal-Meksilenoy pri-ting
one
frequencies
In the left ventricle
| Changes in application- + 0.54 + 8.66 + 12.55 +28.42 +47.87 +11.03.03
time I + 24
Mexileprovision of bridges
Amendment - By application - O-1,82-11,8 + 30,84 +43,4 +83,9
SNU 1 + 36
electric-mexyl threshold
Amendment - By application- -0,08 -0.98-9,21-17,09 -28,82 -59,1
GNU 1-32
Maxi-Mexilem Tin drive frequency
Sokrashtsae - 2,61 -7,57-15,5-18,12 -27,08 -37,92
bridge

类似技术:

公开号 | 公开日 | 专利标题

SU1498383A3|1989-07-30|Method of producing derivatives of aminoguanidine or their acid-additive salts

US3261859A|1966-07-19|Basically substituted phenyl acetonitrile compounds

WO1994014780A1|1994-07-07|Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors

CA2383781A1|2001-03-08|Sulfonyl carboxamide derivatives, method for their production and their use as medicaments

EP0114878B1|1990-09-26|Phthalazine substituted aminomethyl benzene derivatives, compositions and use

PT87051B|1992-07-31|PROCESS FOR THE PREPARATION OF ANTI-ARRHYTHMIC AGENTS OF INDANO-SULFONAMIDES

GB2084993A|1982-04-21|N-lower-alkyl 3-phenoxy-1-azetidinecarboxamides

DE2160148C2|1984-07-19|Medicines and certain sulphoxides as such

US4505921A|1985-03-19|Sulfonylurea compounds and their use in treating diabetes

US4329347A|1982-05-11|Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril

US4897423A|1990-01-30|Dinitrobenzenesulfonamides

US4235906A|1980-11-25|Bis-isoquinolinium compounds, compositions and methods of use

US3459756A|1969-08-05|N-|)-3-sulfamyl-4-chloro-benzoic acid amide

DE3035688C2|1990-05-17|

US4282212A|1981-08-04|Immune-stimulating 1-|-2-cyanoaziridines

US4031216A|1977-06-21|3-|-3-methyl-piperazines

US4880821A|1989-11-14|α-nitroalkylnitrobenzenesulfonamides

US4500531A|1985-02-19|Therapeutical use of | piperazine derivatives

DE60025270T2|2006-08-17|N-SUBSTITUTED BENZYL OR PHENYL ARYLSULFAMIDES AND THEIR USE

US4703048A|1987-10-27|Novel 1-benzhydryl-4-cinnamylpiperazine derivatives, and pharmaceutical compositions comprising said compounds as active ingredient for treating a cerebrovascular disease

EP0000693A1|1979-02-21|Aminophenoxymethyl-2-morpholine derivatives, the preparation thereof and pharmaceuticals containing them

US3996360A|1976-12-07|Piperazine compounds

US3414614A|1968-12-03|Acetamidine derivatives

US3728389A|1973-04-17|Biologically active amidines and their preparation

US4694020A|1987-09-15|Derivatives of 2-|-6-nitrobenzoic acids and pharmaceutical compositions

同族专利:

公开号 | 公开日

DK164155C|1992-10-12|

AT394192B|1992-02-10|

IL73811D0|1985-03-31|

GB2151617B|1987-06-10|

HU190639B|1986-09-29|

KR850004585A|1985-07-25|

NL8403779A|1985-07-01|

DD228246A5|1985-10-09|

DK595484A|1985-06-13|

BG60757B2|1996-02-29|

NO844978L|1985-06-13|

ATA392384A|1991-08-15|

IL73811A|1988-12-30|

FR2556343B1|1988-03-04|

FI844909A0|1984-12-12|

NO159528C|1989-01-11|

SU1340583A3|1987-09-23|

BG44374A3|1988-11-15|

BG42355A3|1987-11-14|

FI844909L|1985-06-13|

SE8406302D0|1984-12-12|

PL140594B1|1987-05-30|

CH664955A5|1988-04-15|

FI79527C|1990-01-10|

NL193539B|1999-09-01|

GB2151617A|1985-07-24|

JPS60178855A|1985-09-12|

JPH0226629B2|1990-06-12|

NO159528B|1988-10-03|

PL250892A1|1985-12-17|

GB8431312D0|1985-01-23|

BE901239A|1985-06-10|

DK595484D0|1984-12-12|

SE8406302L|1985-06-13|

NL193539C|2000-01-04|

US4731383A|1988-03-15|

DE3445339C2|1989-12-14|

PL142626B1|1987-11-30|

SE462847B|1990-09-10|

DK164155B|1992-05-18|

DE3445339A1|1985-06-13|

KR870001105B1|1987-06-08|

CA1237129A|1988-05-24|

FR2556343A1|1985-06-14|

FI79527B|1989-09-29|

HUT36089A|1985-08-28|

PL255440A1|1986-07-01|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

BE663481A|1964-05-05|

GB1274668A|1968-06-10|1972-05-17|Ici Ltd|Pesticidal compositions comprising aminoguanidines|

DE1768867C3|1968-07-09|1973-12-20|Boehringer Mannheim Gmbh, 6800 Mannheim|Aminoguanidine derivatives, processes for their production and their use for the production of medicaments|

US3803324A|1968-07-09|1974-04-09|Boehringer Mannheim Gmbh|Amino-guanidine derivatives useful for regulating blood pressure|

DE1939738A1|1969-08-05|1971-02-18|Boehringer Mannheim Gmbh|Aminoguanidines and Process for Making Same|

NL7315350A|1973-11-09|1975-05-13|Akzo Nv|NEW AMINOGUANIDINE COMPOUNDS.|US5612332A|1984-03-19|1997-03-18|Alteon Inc.|Di- and triaminoguanidines, and methods of use|

US5852009A|1984-03-19|1998-12-22|The Rockefeller University|Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon|

FR2669927B1|1990-11-29|1994-04-08|Adir Cie|NOVEL GUANIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.|

US5424449A|1994-10-28|1995-06-13|Olin Corporation|Process for the preparation of 5-aminotetrazole|

US5850840A|1995-11-15|1998-12-22|Alteon Inc.|Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts|

US6110968A|1995-12-26|2000-08-29|The Picower Institute For Medical Research|Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts|

US5877217A|1995-12-26|1999-03-02|Alteon Inc.|N-acylaminoalkyl-hydrazinecarboximidamides|

US6693095B2|1997-04-01|2004-02-17|Biochemie Gesellschaft M.B.H.|Antibacterial substituted 7-acylamino-3- methyl-cephalosporins and intermediates|

KR20040000380A|1997-04-01|2004-01-03|바이오케미 게젤샤프트 엠베하|Antibacterial substituted 7-acylamino-3-methyl-cephalosporins and intermediates|

AT405180B|1997-04-01|1999-06-25|Biochemie Gmbh|Novel derivatives of substituted 3-cephem-4-carboxylic acid derivatives and process for their preparation|

FR2771409B1|1997-11-21|2000-01-14|Oreal|NOVEL AZO COMPOUNDS, USE FOR DYEING, COMPOSITIONS CONTAINING THEM AND DYEING METHODS|

US6883592B2|1998-11-04|2005-04-26|Zalman Tech Co., Ltd.|Heatsink for electronic component|

US7180758B2|1999-07-22|2007-02-20|Mks Instruments, Inc.|Class E amplifier with inductive clamp|

FR2804428B1|2000-01-27|2002-03-22|Oreal|NOVEL GUANIDINE CHAIN OXIDATION BASES, PROCESS FOR THEIR PREPARATION, THEIR USE FOR OXIDATION DYEING OF KERATIN FIBERS, TINCTORIAL COMPOSITIONS AND DYEING PROCESSES|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

HU834222A|HU190639B|1983-12-12|1983-12-12|Process for production of new aminoguanidin derivatives|LV930670A| LV5462A3|1983-12-12|1993-06-28|Satisfaction of the acquisition of the Aminoguanidin derivatives or the aditive islands of their claws|

[返回顶部]